Volume 2021, Issue 2
  • EISSN: 2220-2749



Article metrics loading...

Loading full text...

Full text loading...



  1. Wong AH, Roppolo LP, Chang BP, Yonkers KA, Wilson MP, Powsner S, et al. Management of agitation during the COVID-19 pandemic. West J Emerg Med. 2020;
    [Google Scholar]
  2. Garg RK, Paliwal VK, Gupta A. Encephalopathy in patients with COVID-19: A review. Journal of Medical Virology. 2021.
    [Google Scholar]
  3. Kashani KB. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes. Mayo Clinic Proceedings. 2020.
    [Google Scholar]
  4. Martinotti G, Barlati S, Prestia D, Palumbo C, Giordani M, Cuomo A, et al. Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release. Psychopharmacology. 2020.
    [Google Scholar]
  5. Ostuzzi G, Gastaldon C, Papola D, Fagiolini A, Dursun S, Taylor D, et al. Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. Ther Adv Psychopharmacol. 2020;
    [Google Scholar]
  6. Yoon HJ, Park KM, Choi WJ, Choi SH, Park JY, Kim JJ, et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry. 2013;
    [Google Scholar]
  7. Ojeahere MI, de Filippis R, Ransing R, Karaliuniene R, Ullah I, Bytyçi DG, et al. Management of psychiatric conditions and delirium during the COVID-19 pandemic across continents: lessons learned and recommendations. Brain, Behav Immun - Heal. 2020;
    [Google Scholar]
  8. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clinic Proceedings. 2006.
    [Google Scholar]
  • Article Type: Letter to the Editor
Keyword(s): agitationCOVID-19psychiatry and treatment
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error